Skip to main content

Table 1 Clinical trials of CD47/SIRPα-targeted agents in hematological malignancies

From: Targeting macrophages in hematological malignancies: recent advances and future directions

 

Type of mAb

Subclass of IgG

Initial time of clinical studies

Phase

Type of tumors

Treatment programs

ClinicalTrials.gov Identifier

Hu5F9-G4

mAb

IgG4

2014.8

Phase II

MDS and AML

Combined therapy

NCT02216409

Hu5F9-G4

mAb

IgG4

2020.9

Phase III

Higher-risk MDS

Combined therapy

NCT04313881

Hu5F9-G4

mAb

IgG4

2021.11

Phase II

R/R cHL

Combined therapy

NCT04788043

Hu5F9-G4

mAb

IgG4

2021.12

Phase I

R/R B-Malignancies

Combined therapy

NCT04599634

Hu5F9-G4

mAb

IgG4

2022.05

Phage III

TP53 Mutant AML

Combined therapy

NCT04778397

Hu5F9-G4

mAb

IgG4

2022.9

Phase IB/II

MDS and AML

Combined therapy

NCT05367401

TTI-621

SIRPα fusion protein

IgG1

2016.1

Phase IA/IB

Hematological Malignancies

Monotherapy

NCT02663518

TTI-621

SIRPα fusion protein

IgG1

2021.10

Phase IB

MM

Combined therapy

NCT05139225

TTI-622

SIRPα fusion protein

IgG4

2018.5

Phase IA/IB

Hematological Malignancies

Combined therapy

NCT03530683

TTI-622

SIRPα fusion protein

IgG4

2021.1

Phase IB

R/R MM

Combined therapy

NCT05139225

ALX148

IRPα fusion protein

IgG1

2017.2

Phase I

Lymphoma

Combined therapy

NCT03013218

ALX148

SIRPα fusion protein

IgG1

2020.1

Phase I/II

MDS

Combined therapy

NCT04417517

ALX148

SIRPα fusion protein

IgG1

2021.1

Phase I/II

B-NHL

Combined therapy

NCT05025800

ALX148

SIRPα fusion protein

IgG1

2021.5

Phase I/II

AML

Combined therapy

NCT04755244

AK117

mAb

IgG4

2020.4

Phase I

Lymphoma

Monotherapy

NCT04349969

AK117

mAb

IgG4

2021.1

Phase I

Lymphoma

Monotherapy

NCT04728334

AK117

mAb

IgG4

2021.5

Phase I/II

Higher-risk MDS

Combined therapy

NCT04900350

AK117

mAb

IgG4

2021.7

Phase IB/II

AML

Combined therapy

NCT04980885

Gentulizumab

mAb

Un

2021.4

Phase I

NHL

Combined therapy

NCT05221385

Gentulizumab

mAb

Un

2021.4

Phase I

R/R-AML or MDS

Monotherapy

NCT05263271

IMM-01

SIRPα fusion protein

IgG1

2019.9

Phase I

Lymphoma

Monotherapy

ChiCTR1900024904

IMM-01

SIRPα fusion protein

IgG1

2022.1

Phase I/II

MDS and AML

Combined therapy

NCT05140811

SRF231

mAb

IgG4

2018.3

Phase IA/IB

lymphoma/CLL

Combined therapy

NCT03512340

SHR1603

mAb

IgG4

2018.1

Phase I

Lymphoma

Combined therapy

NCT03722186

IBI188

mAb

IgG4

2018.12

Phase I

lymphoma

Combined therapy

NCT03717103

IBI188

mAb

IgG4

2020.8

Phase IB

Newly Diagnosed HR-MDS

Combined therapy

NCT04511975

IBI188

mAb

IgG4

2020.9

Phase IB

AML

Combined therapy

NCT04485052

IBI188

mAb

IgG4

2020.9

Phase IB

Newly Diagnosed HR-MDS

Combined therapy

NCT04485065

TJC4

mAb

IgG4

2019.5

Phase I

lymphoma

Combined therapy

NCT03934814

TJC4

mAb

IgG4

2021.6

Phase IB

MDS and AML

Combined therapy

NCT04912063

TJC4

mAb

IgG4

2022.1

Phase IB

Multiple Myeloma

Combined therapy

NCT04895410

ZL-1201

mAb

IgG4

2020.5

Phase I

Lymphoma

Combined therapy

NCT04257617

IMC-002

mAb

IgG4

2020.6

Phase I

Lymphoma

Combined therapy

NCT04306224

AO-176

mAb

IgG2

2020.11

Phase I/II

Multiple Myeloma

Combined therapy

NCT04445701

CC-95251

mAb

IgG4

2019.2

Phase I

Hematological Cancers

Combined therapy

NCT03783403

CC-95251

mAb

IgG4

2022.1

Phase I

MDS and AML

Combined therapy

NCT05168202

CD47

mAb

Un

2021.12

Single-arm

Recurrent AML After Transplantation

Combined therapy

NCT05266274

  1. Un Unknown